Intensity Therapeutics

OverviewSuggest Edit

Intensity Therapeutics is a clinical-stage biotechnology company that applies an immune-based approach to treat solid tumor cancers. It uses the DfuseRxSM technology platform to create drug formulations that disperse throughout a tumor and diffuse therapeutic agents into cancer cells. The company is also engaged in the development of INT230-6, a drug candidate that can be used to treat injected and non-injected tumors as well as micro-metastases.
TypePrivate
Founded2012
HQWestport, CT, US
Websiteintensitytherapeutics.com

Latest Updates

Employees (est.) (Apr 2021)11
Cybersecurity ratingAMore

Key People/Management at Intensity Therapeutics

Ian B. Walters

Ian B. Walters

Chief Medical Officer
Syed Mahmood

Syed Mahmood

Senior Vice President Clinical Development
Rebecca Drain

Rebecca Drain

Executive Director, Regulatory Affairs
Lewis H. Bender

Lewis H. Bender

Founder and CEO
Show more

Intensity Therapeutics Office Locations

Intensity Therapeutics has an office in Westport
Westport, CT, US (HQ)
61 Wilton Rd 3rd floor
Show all (1)

Intensity Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

Intensity Therapeutics total Funding

$11.5 m

Intensity Therapeutics latest funding size

$10 m

Time since last funding

5 years ago
Intensity Therapeutics's latest funding round in June 2016 was reported to be $10 m. In total, Intensity Therapeutics has raised $11.5 m
Show all financial metrics

Intensity Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Intensity Therapeutics Online and Social Media Presence

Embed Graph

Intensity Therapeutics Blogs

Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer

WESTPORT, Conn. & OTTAWA, Ontario & TORONTO — Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company developing proprietary, intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced that following receip…

Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411)

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced new efficacy and safety data from the ongoing Phase 1/2 clinical study of INT230-6, the Co…

2020 SITC Abstract 411

2020 SITC Abstract 411 Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. The post 2020 SITC Abstract 411 appeared first on Intensity Therapeutics.

Intensity Therapeutics Frequently Asked Questions

  • When was Intensity Therapeutics founded?

    Intensity Therapeutics was founded in 2012.

  • Who are Intensity Therapeutics key executives?

    Intensity Therapeutics's key executives are Ian B. Walters, Syed Mahmood and Rebecca Drain.

  • How many employees does Intensity Therapeutics have?

    Intensity Therapeutics has 11 employees.

  • Who are Intensity Therapeutics competitors?

    Competitors of Intensity Therapeutics include Bold Therapeutics, Iksuda Therapeutics and Calidi Biotherapeutics.

  • Where is Intensity Therapeutics headquarters?

    Intensity Therapeutics headquarters is located at 61 Wilton Rd 3rd floor, Westport.

  • Where are Intensity Therapeutics offices?

    Intensity Therapeutics has an office in Westport.

  • How many offices does Intensity Therapeutics have?

    Intensity Therapeutics has 1 office.